This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Medlab Clinical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
Anahtar bilgiler
-18.9%
Kazanç büyüme oranı
-7.9%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 9.6% |
Gelir büyüme oranı | -19.2% |
Özkaynak getirisi | -108.3% |
Net Marj | -541.7% |
Son Kazanç Güncellemesi | 30 Jun 2022 |
Yakın geçmiş performans güncellemeleri
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Gelir ve Gider Dağılımı
Medlab Clinical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 22 | 2 | -8 | 12 | 2 |
31 Mar 22 | 1 | -9 | 9 | 1 |
31 Dec 21 | 4 | -12 | 11 | 1 |
30 Sep 21 | 4 | -12 | 11 | 2 |
30 Jun 21 | 1 | -10 | 11 | 2 |
31 Mar 21 | 1 | -10 | 10 | 2 |
31 Dec 20 | 1 | -11 | 9 | 2 |
30 Sep 20 | 2 | -12 | 9 | 2 |
30 Jun 20 | 3 | -13 | 10 | 2 |
31 Mar 20 | 4 | -12 | 10 | 2 |
31 Dec 19 | 4 | -12 | 11 | 2 |
30 Sep 19 | 5 | -10 | 10 | 1 |
30 Jun 19 | 5 | -8 | 10 | 1 |
31 Mar 19 | 5 | -7 | 8 | 1 |
31 Dec 18 | 5 | -6 | 7 | 0 |
30 Sep 18 | 4 | -5 | 7 | 0 |
30 Jun 18 | 4 | -5 | 6 | 0 |
31 Mar 18 | 4 | -4 | 6 | 0 |
31 Dec 17 | 5 | -4 | 6 | 0 |
30 Sep 17 | 5 | -4 | 5 | 0 |
30 Jun 17 | 4 | -4 | 5 | 0 |
31 Mar 17 | 4 | -4 | 5 | 0 |
31 Dec 16 | 4 | -4 | 4 | 0 |
30 Sep 16 | 3 | -4 | 4 | 0 |
30 Jun 16 | 3 | -3 | 4 | 0 |
Kaliteli Kazançlar: MDC is currently unprofitable.
Büyüyen Kar Marjı: MDC is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Büyüme Hızlandırma: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
Özkaynak Getirisi
Yüksek ROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.